AACR20: does intermittent dosing of targeted agents impact survival of BRAF+ melanoma patients?

Previous research has suggested that intermittent dosing of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) could delay acquired resistance in BRAF mutation-positive melanoma patients. In light of this, a multi-institutional team of researchers in the US has investigated the effects of intermittent dosing compared to continuous dosing of dabrafenib and trametinib on progression-free survival (PFS).  The randomized, Phase II trial (NCT02196181), termed S1320, is due to be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I (27–28 April 2020). Led by the University of California San Francisco (CA, USA), the study involved 242 patients. All patients...